糖尿病護理設備市場：商業機會、成長要素、產業趨勢分析及2026-2035年預測

Diabetes Care Devices Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035

出版日期: 2026年07月13日 | 出版商:

Global Market Insights Inc. | 英文 134 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球糖尿病護理設備市場預計到 2025 年將價值 592 億美元，年複合成長率為 12.4%，到 2035 年將達到 1,888 億美元。

隨著糖尿病盛行率的不斷上升，對能夠有效管理疾病和提供長期患者照護的先進解決方案的需求持續強勁。全球糖尿病護理設備市場也受惠於對微創和穿戴式科技日益成長的需求，這些技術能夠實現持續的健康監測，同時提升患者的舒適度。這些醫療設備在血糖值監測、胰島素給藥和整體糖尿病管理中發揮著至關重要的作用，透過提高治療的準確性和便利性，幫助患者更好地控制病情。公共和私人機構不斷增加的財政支持，透過推廣預防措施、早期診斷項目和長期疾病管理策略，進一步加速了市場成長。對數位醫療基礎設施、穿戴式科技和互聯醫療設備的投資，持續加強整個糖尿病照護生態系統，同時使患者更容易獲得先進的治療方案。快速的技術創新仍然是關鍵趨勢，製造商致力於開發經濟高效、方便用戶使用且可靠的糖尿病護理設備，以改善臨床表現，並在各種醫療環境中支持改善患者的治療效果。

市場範圍
開始年份	2025
預測期	2026-2035
上市時的市場規模	592億美元
預計金額	1888億美元
複合年成長率	12.4%

預計到2025年，醫療設備市場規模將達到405億美元，到2035年將達到1,309億美元，複合年成長率（CAGR）為12.6%，這主要得益於先進糖尿病管理技術的廣泛應用。血糖值監測系統和胰島素輸註解決方案的持續創新正在推動治療精準度的提高、疾病管理的簡化以及患者依從性的增強。對精準血糖監測和高效胰島素輸注日益成長的需求預計將在整個預測期內保持強勁成長。

預計到2025年，居家照護產業規模將達到260億美元。隨著人們越來越重視自主疾病管理、提高便利性和長期治療效率，對居家糖尿病照護解決方案的需求持續成長。連線健診技術、遠端患者監護和遠距醫療服務的擴展，透過實現持續的健康追蹤和患者與遠端醫療服務提供者之間的無縫溝通，進一步推動了該行業的發展。人們對微創和易用型設備的日益偏好，也促進了這些設備在居家照護領域的持續普及。

到2025年，北美糖尿病護理設備市佔率將達到41.9%。該地區市場擴張的驅動力在於糖尿病患者人數的不斷增加以及對長期疾病管理解決方案日益成長的需求。文明病的日益普遍，加上人口老化，導致患者群體持續擴大，從而對先進的糖尿病護理技術和互聯醫療設備產生了持續的需求。

產業生態系分析
影響產業的因素
- 促進因素
  - 糖尿病在全球的盛行率正在上升。
  - 糖尿病照護設備的技術進步
  - 增加對糖尿病照護的公共和私人投資
  - 對微創和穿戴式裝置的需求日益成長
- 產業潛在風險與挑戰
  - 糖尿病照護設備高成本
  - 嚴格的法律規範
  - 連網型設備的隱私、網路安全和合規風險
- 市場機遇
  - 結合了動態血糖監測、胰島素注射和遠端醫療。
  - 人工智慧驅動的決策支援和封閉回路型自動化胰島素給藥
成長潛力分析
監理情勢
- 北美洲
- 歐洲
- 亞太地區
技術進步
- 最新科技趨勢
- 新興技術
  - 非侵入性血糖監測技術
  - 奈米科技的應用
糖尿病的流行病學和疾病負擔分析
- 各地區糖尿病盛行率趨勢
- 妊娠糖尿病的盛行率
- 併發症發生率和醫療費用
糖尿病治療設備創新專利趨勢分析
新興技術臨床試驗流程評估
關鍵設備組件的供應鏈風險分析
糖尿病護理設備中的患者行為和技術採納趨勢
贖回方案
- 編碼與兌換
- 胰島素給藥系統的報銷政策和公共醫療保險覆蓋範圍。
  - 美國
  - 歐洲
價格趨勢分析
未來市場趨勢
差距分析
人工智慧和生成式人工智慧對市場的影響
波特的分析
PESTLE分析

第4章競爭情勢

介紹
企業矩陣分析
企業市佔率分析
- 世界
- 北美洲
- 歐洲
- 亞太地區
- LAMEA
主要市場公司的競爭分析
競爭定位矩陣
主要進展
- 併購
- 夥伴關係和聯盟
- 新產品發布
- 業務拓展計劃

第5章市場估價與預測：依產品分類，2022-2035年

裝置
- 血糖值測量裝置
  - 自測血糖儀
  - 持續血糖監測
- 胰島素輸注裝置
  - 胰島素幫浦
    - 管式幫浦
    - 無內胎幫浦
  - 筆式注射器
    - 可重複使用的
    - 拋棄式的
  - 其他胰島素輸送裝置
消耗品
- 測試條
- 《採血針》
- 筆針
  - 標準
  - 安全
- 注射器
- 胰島素幫浦耗材

第6章市場估算與預測：依最終用途分類，2022-2035年

醫院
門診手術中心
診斷中心
居家照護
其他最終用戶

第7章市場估計與預測：依地區分類，2022-2035年

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- UAE

第8章：公司簡介

Abbott Laboratories
ARKRAY
Ascensia Diabetes Care
B. Braun Melsungen
Becton, Dickinson and Company
Bionime
DarioHealth
Dexcom
Dr. Reddy's Laboratories
Eli Lilly and Company
F. Hoffmann-La Roche
Insulet
LifeScan
Medtronic
Nova Biomedical
Novo Nordisk
Pendiq
Sanofi
Sinocare
Tandem Diabetes Care
Ypsomed Holding

簡介目錄

Product Code: 3250

The Global Diabetes Care Devices Market was valued at USD 59.2 billion in 2025 and is estimated to grow at a CAGR of 12.4% to reach USD 188.8 billion by 2035.

Rising diabetes prevalence continues to create strong demand for advanced solutions that support effective disease management and long-term patient care. The global diabetes care devices market is also benefiting from increasing preference for minimally invasive and wearable technologies that improve patient comfort while enabling continuous health monitoring. These medical devices play an essential role in blood glucose monitoring, insulin administration, and overall diabetes management, allowing patients to better manage their condition through improved treatment accuracy and convenience. Growing financial support from both public and private organizations is further accelerating market expansion by encouraging prevention initiatives, early diagnosis programs, and long-term disease management strategies. Investments in digital healthcare infrastructure, wearable technologies, and connected medical devices continue to strengthen the overall diabetes care ecosystem while improving patient access to advanced treatment solutions. Rapid technological innovation remains a key market trend, with manufacturers focusing on developing cost-effective, user-friendly, and highly reliable diabetes care devices that deliver improved clinical performance and support better patient outcomes across diverse healthcare settings.

Market Scope
Start Year	2025
Forecast Year	2026-2035
Start Value	$59.2 Billion
Forecast Value	$188.8 Billion
CAGR	12.4%

The devices segment generated USD 40.5 billion in 2025 and is anticipated to reach USD 130.9 billion by 2035, registering a CAGR of 12.6%, supported by increasing adoption of advanced diabetes management technologies. Continuous innovation in glucose monitoring systems and insulin delivery solutions continues to improve treatment precision, simplify disease management, and enhance patient compliance. Growing demand for accurate glucose monitoring and efficient insulin administration is expected to maintain strong growth throughout the forecast period.

The home care segment accounted for USD 26 billion in 2025. Rising emphasis on independent disease management, greater convenience, and long-term treatment efficiency continues to drive demand for home-based diabetes care solutions. The expansion of connected healthcare technologies, remote patient monitoring, and telehealth services has further strengthened this segment by enabling continuous health tracking and seamless communication between patients and healthcare professionals. Increasing preference for minimally invasive, easy-to-use devices is also supporting sustained adoption across home care environments.

North America Diabetes Care Devices Market captured 41.9% share in 2025. Market expansion across the region is being driven by the growing number of individuals living with diabetes and the increasing need for long-term disease management solutions. Rising rates of lifestyle-related health conditions, together with an aging population, continue to expand the patient base, creating sustained demand for advanced diabetes care technologies and connected medical devices.

Major companies operating in the global diabetes care devices market include Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, Becton Dickinson and Company, Bionime, DarioHealth, Dexcom, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, Insulet, Medtronic, Nova Biomedical, Novo Nordisk, Pendiq, LifeScan, Sanofi, Sinocare, Tandem Diabetes Care, and Ypsomed Holding. Companies operating in the diabetes care devices market continue to strengthen their market position by investing heavily in research and development to introduce innovative, connected, and patient-centric solutions. Manufacturers are focusing on integrating digital health technologies, wearable platforms, and advanced data management capabilities to improve treatment outcomes and enhance patient engagement. Product portfolio expansion, continuous technological innovation, and development of minimally invasive devices remain important competitive strategies. Strategic partnerships, regulatory approvals, and broader geographic expansion are also helping companies increase market penetration and strengthen customer reach.

Chapter 1 Research Methodology

1.1 Research approach
1.2 Quality commitments
- 1.2.1 GMI AI policy & data integrity commitment
  - 1.2.1.1 Source consistency protocol
1.3 Research trail & confidence scoring
- 1.3.1 Research trail components
- 1.3.2 Scoring components
1.4 Data collection
- 1.4.1 Partial list of primary sources
1.5 Data mining sources
- 1.5.1 Paid sources
  - 1.5.1.1 Sources, by region
1.6 Base estimates and calculations
- 1.6.1 Base year calculation
1.7 Forecast model
- 1.7.1 Quantified market impact analysis
  - 1.7.1.1 Mathematical impact of growth parameters on forecast
1.8 Research transparency addendum
- 1.8.1 Source attribution framework
- 1.8.2 Quality assurance metrics
- 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

2.1 Industry 360° synopsis
2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Product trends
- 2.2.3 End use trends
2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of diabetes across the world
  - 3.2.1.2 Rising technological advancements in diabetes care devices
  - 3.2.1.3 Increasing investments by public and private organizations for diabetes care
  - 3.2.1.4 Increasing demand for minimally invasive and wearable devices
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of diabetes care devices
  - 3.2.2.2 Rigorous regulatory framework
  - 3.2.2.3 Privacy, cybersecurity, and compliance risks in connected devices
- 3.2.3 Market opportunities
  - 3.2.3.1 Integrated care models combining CGM, insulin delivery, and telehealth
  - 3.2.3.2 AI-enabled decision support and closed-loop insulin automation
3.3 Growth potential analysis
3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
3.5 Technological advancements
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
  - 3.5.2.1 Non-Invasive glucose monitoring technologies
  - 3.5.2.2 Nanotechnology applications
3.6 Diabetes epidemiology and disease burden analysis
- 3.6.1 Regional diabetes prevalence trends
- 3.6.2 Gestational diabetes prevalence
- 3.6.3 Complication rates and healthcare costs
3.7 Patent landscape analysis for diabetes device innovations
3.8 Clinical trial pipeline assessment for emerging technologies
3.9 Supply chain risk analysis for key device components
3.10 Patient behavior and technology adoption patterns in diabetes care devices
3.11 Reimbursement scenario
- 3.11.1 Coding and reimbursement
- 3.11.2 Reimbursement policies and public healthcare sector insurance coverage for insulin delivery systems
  - 3.11.2.1 U.S.
  - 3.11.2.2 Europe
3.12 Pricing trend analysis
3.13 Future market trends
3.14 Gap analysis
3.15 Impact of AI & Generative AI on the Market (Driven by Primary Research)
3.16 Porter's analysis
3.17 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis (Driven by Primary Research)
- 4.3.1 Global
- 4.3.2 North America
- 4.3.3 Europe
- 4.3.4 Asia Pacific
- 4.3.5 LAMEA
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
- 4.6.1 Mergers & acquisitions
- 4.6.2 Partnerships & collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

5.1 Key trends
5.2 Devices
- 5.2.1 Blood glucose monitoring devices
  - 5.2.1.1 Self-monitoring blood glucose meters
  - 5.2.1.2 Continuous glucose monitors
- 5.2.2 Insulin delivery devices
  - 5.2.2.1 Insulin pumps
    - 5.2.2.1.1 Tubed pumps
    - 5.2.2.1.2 Tubeless pumps
  - 5.2.2.2 Pens
    - 5.2.2.2.1 Reusable
    - 5.2.2.2.2 Disposable
  - 5.2.2.3 Other insulin delivery devices
5.3 Consumables
- 5.3.1 Testing strips
- 5.3.2 Lancets
- 5.3.3 Pen needles
  - 5.3.3.1 Standard
  - 5.3.3.2 Safety
- 5.3.4 Syringes
- 5.3.5 Insulin pump consumables

Chapter 6 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

6.1 Key trends
6.2 Hospital
6.3 Ambulatory surgical centers
6.4 Diagnostic centers
6.5 Homecare
6.6 Other end users

Chapter 7 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

7.1 Key trends
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Netherlands
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 South Korea
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Argentina
7.6 MEA
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 UAE